Efficacy of Levofloxacin-based Triple Therapy as Second-lineHelicobacter pylori Eradication / 대한소화기학회지
The Korean Journal of Gastroenterology
;
: 285-290, 2008.
Artículo
en Coreano
| WPRIM
| ID: wpr-17360
ABSTRACT
BACKROUND/AIMS:
Bismuth-based quadruple therapy for second-line eradication treatment achieves the eradication rate ranging from 70% to 81% due to antimicrobial resistance and poor compliance. The aim of this study was to compare the eradication rate of levofloxacin-based triple therapy with that of bismuth-based quadruple therapy in second-line Helicobacter pylori (H. pylori) eradication therapy.METHODS:
Seventy-six outpatients with persistent H. pylori infection after first-line triple therapy were enrolled in this prospective randomized trial. The subjects were randomized to receive levofloxacin 300 mg, amoxicillin 1 g, and pantoprazole 20 mg, given twice daily for 7 days (LAP group), or metronidazole 500 mg twice, tetracycline 500 mg four times, and pantoprazole 20 mg twice, bismuth subcitrate 600 mg twice daily for 7 days (MTPB group). Eradication was confirmed with 13C-urea breath test or rapid urease test 4 weeks after the cessation of therapy.RESULTS:
Among Seventy-six patients initially included, eleven were lost during follow-up. The eradication rates, expressed as intention to treat (ITT) and per protocol (PP) analyses, were 51.6% and 53.3% in the LAP group, and 48.9% and 62.9% in the MTPB group, respectively. There was no significant difference in H. pylori eradication rates between the two groups (p=0.815 by ITT, p=0.437 by PP). LAP regimen was better tolerated than MTPB regimen with lower incidence of side effects (10.0% versus 31.4%, p=0.03).CONCLUSIONS:
H. pylori eradication rates of levofloxacin-based triple therapy and bismuth-based quadruple therapy were not significantly different in second-line H. pylori eradication therapy, and low incidence of side effects was observed in levofloxacin-based triple therapy.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Compuestos Organometálicos
/
Factores de Tiempo
/
Ofloxacino
/
Interpretación Estadística de Datos
/
Helicobacter pylori
/
Infecciones por Helicobacter
/
Resultado del Tratamiento
/
Quimioterapia Combinada
/
2-Piridinilmetilsulfinilbencimidazoles
/
Antiácidos
Tipo de estudio:
Ensayo Clínico Controlado
/
Guía de Práctica Clínica
Límite:
Adulto
/
Femenino
/
Humanos
/
Masculino
Idioma:
Coreano
Revista:
The Korean Journal of Gastroenterology
Año:
2008
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS